Text Size

Eosinophil Markers and Development of Disease in Allergic Rhinitis

This study has been completed.
Sponsor:
Collaborator:
Aarhus University Hospital
Information provided by:
University of Aarhus
ClinicalTrials.gov Identifier:
NCT01192386
First received: August 30, 2010
Last updated: August 31, 2010
Last verified: August 2010
History of Changes
  Purpose

Inflammatory proteins from eosinophil granulocytes in blood from patients with seasonal allergic hayfever have been shown to predict development of asthma at a six-year follow-up. This study is a 15-year follow-up of the same patients to verify earlier results and study disease development.


Condition
Seasonal Allergic Rhinitis

Study Type: Observational
Official Title: Eosinophil Markers and Development of Disease in Allergic Rhinitis. A 15-year Follow-up of Patients With Grass Pollen Induced Hayfever.

Resource links provided by NLM:

MedlinePlus related topics: Asthma Hay Fever
U.S. FDA Resources

Further study details as provided by University of Aarhus:

Primary Outcome Measures:
  • Asthma morbidity [ Time Frame: Single measurement - May 2010 ] [ Designated as safety issue: No ]
    Patients are asked whether they have experienced asthmatic symptoms or have been disgnosed with asthma within the latest 15 years


Secondary Outcome Measures:
  • Rhinitis morbidity [ Time Frame: Single measurement - May 2010 ] [ Designated as safety issue: No ]
    Patients are asked for current hayfever symptoms


Enrollment: 29
Study Start Date: May 2010
Study Completion Date: May 2010
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Detailed Description:

The study consists of a single visit at which patients fill in a questionnaire on actual hayfever and asthma symptoms as well as current treatment. Blood samples and nasal lavages are drawn and analysed for eosinophils as well as eosinophil cationic protein and tryptase. Spirometry is performed.

If patients use drugs which can interfere with results, ie. corticosteroids or beta-agonists, biochemistry and/or spirometry are omitted.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Follow-up on participants in Allergic Rhinitis study 1995.

Criteria

Inclusion Criteria:

  • Participant in earlier study (1995)

Exclusion Criteria:

  • Treatment with any kind of corticosteroid within two months will exclude from study of inflammatory parameters
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01192386

Sponsors and Collaborators
University of Aarhus
Aarhus University Hospital
Investigators
Principal Investigator: Lars Peter Nielsen, MD Department of Respiratory Research, Aarhus University Hospital, DK-8000 Aarhus C, Denmark
  More Information

No publications provided

Responsible Party: Ass. professor Lars Peter Nielsen, Department of Respiratory Research, Aarhus University Hospital
ClinicalTrials.gov Identifier: NCT01192386     History of Changes
Other Study ID Numbers: RHINO2010
Study First Received: August 30, 2010
Last Updated: August 31, 2010
Health Authority: Denmark: Ethics Committee
Denmark: Danish Dataprotection Agency

Additional relevant MeSH terms:
Rhinitis, Allergic, Seasonal
Rhinitis
Nose Diseases
Respiratory Tract Diseases
Respiratory Hypersensitivity
 Otorhinolaryngologic Diseases
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Respiratory Tract Infections

ClinicalTrials.gov processed this record on May 16, 2013